Cladribine and CLL

In this randomised phase III study, the efficacy and safety of cladribine and fludarabine, two purine analogues, were compared. Patients (n = 233) with chronic lymphocytic leukaemia were randomised to receive cladribine,

fludarabine or chlorambucil for six cycles along with health-related quality-of-life assessments. The primary end point was overall survival (OS). Results showed that while there was no statistical difference among the treatment arms for OS, median progression-free survival (25, 10, 9 months) and median time to second treatment (40, 22, 21 months) were superior with cladribine. For more information, click here to read the full article.


Global Database

Information by country, region and/or subtype on treatments, clinical trials and incidence/mortality rates.

Resource Library

Over 2,000 pieces of information on lymphoma diagnosis, treatment, research, support and lifestyle.

logo europe


Have you ever attended a meeting with a lymphoma support group?




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or
require more detailed information on the best course of treatment for you.

Our website does not host any form of advertisement. Last updated: 03/27/18. Copyright © 2018 Lymphoma Coalition. All rights reserved.